Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 254-261

  Olson, Linda J ^a   Knych Jr , Edward T ^b   Herzig, Thomas C ^a   Drewett, James G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

cyclic GMP; endothelium derived relaxing factor; guanylyl cyclase; natriuretic peptides; nitric oxide; nitric oxide synthase; vasodilatation

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0031028506     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.254     Document Type: Article

References (48)

1. Drewett JG, Garbers DL. The family of guanylyl cyclase-receptors, their ligands and functions. Endocrine Rev. 1994;15:135-162.
2. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization beyond nitric oxide and cyclic GMP. Circulation. 1995;92: 3337-3349.
3. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 1987;39:163-196.
4. Nakatsu K, Diamond J. Role of cGMP in relaxation of vascular and other smooth muscle. Can J Physiol Pharmacol. 1989;67:251-262.
5. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7:328-338.
6. Isono T, Koibuchi Y, Sata N, Furuichi A, Nishii M, Yamamoto T, Mori J, Kohsaka M, Ohtsuka M. Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993;246:205-212.
7. Bolotina VM, Najibi S, Palacino JJ, Pangano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle cells. Nature (Lond). 1994;368:850-853.
8. Diamond J. Effects of LY83583, nordihydroguaiaretic acid, and quinacrine on cyclic GMP elevation and inhibition of tension by muscarinic agonists in rabbit aorta and left atrium. Can J Physiol Pharmacol. 1987;65:1913-1917.
9. Malta E, Macdonald PS, Dusting GJ. Inhibition of vascular smooth muscle relaxation by LY83583. Naunyn Schmiedebergs Arch Pharmacol. 1988;337:459-464.
10. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993;45:367-374.
11. Luo D, Das S, Vincent SR. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol. 1995;290:247-251.
12. Wolin MS, Cherry PD, Rodenburg JM, Messina EJ, Kaley G. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther. 1990;254:872-876.
13. Brune B, Schmidt K-U, Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem. 1990;192:683-688.
14. Schmidt MJ, Sawyer DB, Truex LL, Marshall WS, Fleich JH. LY83583: an agent that lowers intracellular levels of cyclic guanosine 3′:5′-monophosphate. J Pharmacol Exp Ther. 1985;232: 764-769.
15. Mulsch A, Busse R, Liebau S, Forstermann U. LY83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther. 1988;247:283-288.
16. Mulsch A, Luckhoff A, Pohl U, Busse R, Bassenge E. LY83583 (6-anilino-5,8-quinolinedione blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet aggregation. Naunyn Schmeidebergs Arch Pharmacol. 1989;340:119-125.
17. Cherry PD, Omar HA, Farrell KA, Stuart JS, Wolin MS. Superoxide anion inhibits cGMP-associated bovine pulmonary arterial relaxation. Am J Physiol. 1990;25:H1056-H1062.
18. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995;48:184-188.
19. Hrabie JA, Klose JR, Wink DA, Keefer LK. New nitric oxide-releasing zwitterions derived from polyamines. J Org Chem. 1993; 58:1472-1476.
20. Potter LR, Garbers DL. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J Biol Chem. 1992;267:14531-14534.
21. Chrisman TD, Schulz S, Potter LR, Garbers DL. Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J Biol Chem. 1993;268:3698-3703.
22. Vaandrager AB, Schulz S, De Jonge HR, Garbers DL. Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heal-stable enterotoxin-binding proteins in the intestine. J Biol Chem. 1993;268:2174-2179.
23. Thompson DK, Garbers DL. Dominant negative mutations of the guanylyl cyclase-A receptor. J Biol Chem. 1995;270:425-430.
24. Kriegler M. DNA transfer. In: Gene Transfer and Expression. New York, NY: Stockton Press; 1990:99-100.
25. Yuen PST, Doolittle LK, Garbers DL. Dominant negative mutants of the nitric oxide-sensitive guanylyl cyclase. J Biol Chem. 1994;269: 791-793.
26. Harteneck C, Koesling D, Soling A, Schultz G, Bohme E. Expression of soluble guanylate cyclase: catalytic activity requires two enzyme subunits. FEBS Lett. 1990;272:221-223.
27. Nakane M, Arai K, Saheki S, Kuno T, Buechler W, Murad F. Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem. 1990;265:16841-16845.
28. Harteneck C, Wedel B, Koesling D, Malkewitz J, Bohme E, Schultz G. Molecular cloning and expression of a new α-subunit of soluble guanylyl cyclase. FEBS Lett. 1991;292:217-222.
29. Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun. 1991;174:351-357.
30. Diglio CA, Grammas P, Giacomelli F, Wiener J. Angiogenesis in rat aorta ring explant cultures. Lab Invest. 1989;60:523-531.
31. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
32. Hansborough JR, Garbers DL. Sodium-dependent activation of sea urchin spermatazoa by speract and monensin. J Biol Chem. 1981; 256:2235-2241.
33. Drewett JG, Fendly BM, Garbers DL, Lowe DG. Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J Biol Chem. 1995;270: 4668-4674.
34. Olson LJ, Lowe DG, Drewett JG. Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell-line. Mol Pharmacol. 1996;50:430-435.
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-253.
36. Schulz S, Green CK, Yuen PST, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1993;63:941-948.
37. ω-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol. 1990;76:219-223.
38. Drewett JG, Trachte GJ, Marchand GR. Atrial natriuretic factor inhibits adrenergic and purinergic neurotransmission in the rabbit isolated vas deferens. J Pharmacol Exp Ther. 1989;248:135-142.
39. van Woerkens LJ, Baas NR, van der Giessen WJ, Verdouw PD. Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil. Cardiovasc Drugs Ther. 1992;6:409-417.
40. Gross GJ, Mei DA, Schulz JJ, Mizumura T. Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Basic Res Cardiol. 1996;91:31-34.
41. Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc. 1934;56:658-666.
42. Chrisman TD, Garbers DL, Parks MA, Hardman JG. Characterization of particulate and soluble guanylyl cyclases from rat lung. J Biol Chem. 1975;250:374-381.
43. Cleland WW. Steady-state kinetics. In: Boyer PD, ed. The Enzymes, Vol. 2. 3rd ed. New York, NY: Academic Press; 1970:1-65.
44. Kimura H, Mittal CK, Murad F. Activation of guanylate cyclase from rat liver and other tissues by sodium azide. J Biol Chem. 1975; 250:8016-8022.
45. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Oilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:199-248.
46. Brunner F, Schmidt K, Nielsen EB, Mayer B. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J Pharmacol Exp Ther. 1996;277:48-53.
47. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a)quinoxalin-1-one as a hemesite inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996;50:1-5.
48. + channels in arterial smooth muscle. Science. 1989;245:177-180.